Fig. 3From: Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)The graphic shows MHDs variations from baseline to V6 in normal-weight compared with over-weight CM patientsBack to article page